4
Changes in Ownership
Bambusa Therapeutics, Inc. Filed Acc 0001231919-26-001533
Director bought 2,953,820 shares at an average $15.79 ($46,639,957)
- Director acquired 4,475,938 shares (conversion)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. Director | 2026-10-30 | Purchase | +189,909 | $14.23 | $2,702,405 | 189,909 | I |
| RA CAPITAL MANAGEMENT, L.P. Director | 2026-10-30 | Purchase | +263,911 | $14.92 | $3,937,552 | 453,820 | I |
| RA CAPITAL MANAGEMENT, L.P. Director | 2026-11-02 | Conversion | +3,144,858 | 3,598,678 | I | ||
| RA CAPITAL MANAGEMENT, L.P. Director | 2026-11-02 | Conversion | +1,331,080 | 1,331,080 | I | ||
| RA CAPITAL MANAGEMENT, L.P. Director | 2026-11-02 | Purchase | +2,335,109 | $16.00 | $37,361,744 | 5,933,787 | I |
| RA CAPITAL MANAGEMENT, L.P. Director | 2026-11-02 | Purchase | +164,891 | $16.00 | $2,638,256 | 1,495,971 | I |
| Derivatives | |||||||
| RA CAPITAL MANAGEMENT, L.P. Director | 2026-11-02 | Conversion · Series A-1 Preferred Stock | −2,844,910 | 0 | I | ||
| RA CAPITAL MANAGEMENT, L.P. Director | 2026-11-02 | Conversion · Series A-1 Preferred Stock | −1,278,148 | 0 | I | ||
| RA CAPITAL MANAGEMENT, L.P. Director | 2026-11-02 | Conversion · Series A-2 Preferred Stock | −299,948 | 0 | I | ||
| RA CAPITAL MANAGEMENT, L.P. Director | 2026-11-02 | Conversion · Series A-2 Preferred Stock | −52,932 | 0 | I | ||
| Open-market purchases · 2,953,820 sh · avg $15.79 · $46,639,957 | |||||||
Loading xslF345X06/form4-11032026_111149.xml…